In this study we tried to investigate the influences of targeting STAT3 on ICD of HCC cells in vitro and in vivo, and clarify how STAT3 inhibition improves the tumour immune microenvironment by directly disturbing the glycolysis pathway and balance between “eat me” and “don't eat me” molecules in HCC, thus providing a solid experimental basis for treatment strategies and clinical trials of HCC. This evidence concerns the gene STAT3 and neoplasm.